Literature DB >> 19578852

Prevalence of positive ppd in a cohort of rheumatoid arthritis patients.

Maria Natalia Tamborenea1, Guillermo Tate, Eduardo Mysler, Jose Debonis, Adrian Schijedman.   

Abstract

The main objective of this study is to determine the prevalence of positive and anergic tuberculin skin test (ppd) in a rheumatoid arthritis cohort of patients (RA) and assess the association among ppd results and clinical and treatment variables. Patients with RA diagnosis were included. The ppd was done by Mantoux method. Positive result was considered when indurations were equal or greater than 5 mm. Anergic reaction was defined when the indurations was 0 mm. We included 105 patients (N = 105). The prevalence of positive ppd was 12.4% (n = 13), while the 87.6% (n = 92) presented a negative result. The 69.5% (n = 73) of the population were anergic to ppd. Patients with negative result received higher steroids dosages than patients with positive ppd (p < 0.04). In the multivariable model, the steroids dosage was a significant and independent predictor of negative ppd (p = 0.021, OR 0.72, 95% CI 0.55-0.95). Anergic and non-anergic patients were separated in groups, and a new analysis was done. The higher dosage of methotrexate was associated to tuberculine anergy (p = 0.025). In the multivariable model, the methotrexate dosage was a significant and independent predictor of tuberculine anergy (p = 0.005, OR 1.14, 95% CIs 1.04-1.24). In conclusion, in our cohort, the prevalence of positive ppd was lower than others studies. Among analyzed variables, the high steroid dose was a significant and independent predictor of negative ppd. The methotrexate treatment and dose were associated with ppd anergy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19578852     DOI: 10.1007/s00296-009-1027-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  16 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments.

Authors:  J Ledingham; C Wilkinson; C Deighton
Journal:  Rheumatology (Oxford)       Date:  2005-10       Impact factor: 7.580

3.  The relative proportions of secreted interleukin-2 and interleukin-10 determine the magnitude of rheumatoid arthritis T-cell proliferation to the recall antigen tuberculin purified protein derivative.

Authors:  V M Corrigall; A Garyfallos; G S Panayi
Journal:  Rheumatology (Oxford)       Date:  1999-12       Impact factor: 7.580

4.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

Review 5.  Tumor necrosis factor is critical to control tuberculosis infection.

Authors:  Muazzam Jacobs; Dieudonnée Togbe; Cecile Fremond; Arina Samarina; Nasiema Allie; Tania Botha; Daniela Carlos; Shreemanta K Parida; Sergei Grivennikov; Sergei Nedospasov; Analbery Monteiro; Marc Le Bert; Valerie Quesniaux; Bernhard Ryffel
Journal:  Microbes Infect       Date:  2007-02-21       Impact factor: 2.700

6.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

7.  Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.

Authors:  Johan Askling; C Michael Fored; Lena Brandt; Eva Baecklund; Lennart Bertilsson; Lars Cöster; Pierre Geborek; Lennart T Jacobsson; Staffan Lindblad; Jörgen Lysholm; Solbritt Rantapää-Dahlqvist; Tore Saxne; Victoria Romanus; Lars Klareskog; Nils Feltelius
Journal:  Arthritis Rheum       Date:  2005-07

8.  Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis.

Authors:  D Ponce de León; E Acevedo-Vásquez; A Sánchez-Torres; M Cucho; J Alfaro; R Perich; C Pastor; J Harrison; C Sánchez-Schwartz
Journal:  Ann Rheum Dis       Date:  2005-09       Impact factor: 19.103

9.  Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Authors:  Daniel E Furst; Michael H Schiff; Roy M Fleischmann; Vibeke Strand; Charles A Birbara; Daniele Compagnone; Steven A Fischkoff; Elliot K Chartash
Journal:  J Rheumatol       Date:  2003-12       Impact factor: 4.666

10.  Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay.

Authors:  G Matulis; P Jüni; P M Villiger; S D Gadola
Journal:  Ann Rheum Dis       Date:  2007-07-20       Impact factor: 19.103

View more
  6 in total

Review 1.  Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.

Authors:  Raja K Sivamani; Heidi Goodarzi; Miki Shirakawa Garcia; Siba P Raychaudhuri; Lisa N Wehrli; Yoko Ono; Emanual Maverakis
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

2.  Increased detection of latent tuberculosis by tuberculin skin test and booster phenomenon in early rheumatoid arthritis patients.

Authors:  L Pérez-Barbosa; J A Esquivel-Valerio; A C Arana-Guajardo; D Vega-Morales; J Riega-Torres; M A Garza-Elizondo
Journal:  Rheumatol Int       Date:  2015-03-14       Impact factor: 2.631

Review 3.  [Screening investigations during intensified immunosuppression in children and adolescents. Part 1].

Authors:  F Speth; N Wellinghausen; J-P Haas
Journal:  Z Rheumatol       Date:  2013-10       Impact factor: 1.372

4.  QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment.

Authors:  Hyun Lee; Hye Yun Park; Kyeongman Jeon; Byeong-Ho Jeong; Ji-Won Hwang; Jaejoon Lee; Hoon-Suk Cha; Eun-Mi Koh; Eun-Suk Kang; Won-Jung Koh
Journal:  PLoS One       Date:  2015-03-06       Impact factor: 3.240

5.  Frequency of positivity of the tuberculin intradermorreaction test in a cohort of patients with rheumatoid arthritis

Authors:  Wilson Bautista-Molano; Liza González; Daniel Fernández-Ávila; Rosa Cardozo; Óscar Ruiz
Journal:  Biomedica       Date:  2021-09-22       Impact factor: 0.935

6.  Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates.

Authors:  Aysa Hacioglu; Sermin Borekci; Melike Melikoglu; Yesim Ozguler; Sinem Nihal Esatoglu; Serdal Ugurlu; Emire Seyahi; Izzet Fresko; Vedat Hamuryudan; Huri Ozdogan; Sebahattin Yurdakul; Ibrahim Hatemi; Aykut Ferhat Celik; H Gul Ongen; Gulen Hatemi
Journal:  Rheumatol Int       Date:  2021-07-06       Impact factor: 3.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.